Figure 643: Figure 67. Hydrocolloid dressing versus alginate dressing – proportion of patients with maceration



Figure 644: Hydrocolloid dressing versus alginate dressing – proportion of patients with bleeding



Figure 645: Hydrocolloid dressing versus alginate dressing – incidence of pain at dressing removal

Figure 646: Hydrocolloid dressing versus alginate dressing – incidence of strong odour at dressing removal

Figure 647: Hydrocolloid dressing versus alginate dressing – incidence of mild odour at dressing removal

Figure 648: Hydrocolloid dressing versus alginate dressing –mortality



Figure 649: Hydrocolloid dressing versus charcoal dressing – proportion of patients worsened



Figure 650: Hydrocolloid dressing versus charcoal dressing – proportion of patients with maceration



Figure 651: Hydrocolloid dressing versus charcoal dressing – proportion of patients with an infection



Figure 652: Hydrocolloid dressing versus charcoal dressing – proportion of patients with hypergranulation



Figure 653: Hydrocolloid dressing versus charcoal dressing – proportion of patients with skin irritation and eczema



Figure 654: Hydrocolloid dressing versus charcoal dressing – proportion of patients with bleeding



Figure 655: Hydrocolloid dressing versus charcoal dressing – proportion of patients with pruritus



Figure 656: Hydrocolloid dressing versus charcoal dressing – proportion of patients with wound pain



Figure 657: Hydrocolloid dressing versus charcoal dressing – proportion of patients with pain at dressing removal



Figure 658: Hydrocolloid dressing versus charcoal dressing – mortality (all-cause)



Figure 659: Figure 79. Hydrocolloid dressing versus phenytoin ointment – mean time to healing (days)



Figure 660: Hydrocolloid dressing versus phenytoin ointment – proportion of people with adverse events



Figure 661: Hydrocolloid dressing versus phenytoin ointment –mortality



Figure 662: Hydrocolloid dressing versus antibiotic ointment – mean time to healing (days)



Figure 663: Hydrocolloid dressing versus antibiotic ointment – proportion of people with adverse events



Figure 664: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients completely healed



Figure 665: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients improved



Figure 666: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients not changed



Figure 667: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients worsened



Figure 668: Hydrocolloid dressing: triangular shape versus oval shape – mean percentage reduction in ulcer length



Figure 669: Hydrocolloid dressing: triangular shape versus oval shape – mean pain at dressing change



Figure 670: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients with ulcer pain



Figure 671: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients with adverse events



Figure 672: Hydrocolloid dressing: SignaDress® versus Comfeel®Plus – proportion of patients completely healed



Figure 673: Hydrocolloid dressing: SignaDress® versus Comfeel®Plus – proportion of people with adverse events



Figure 674: Gauze dressing versus foam dressing – proportion of patients completely healed



Figure 675: Gauze dressing versus foam dressing –mortality



Figure 676: Figure 90. Gauze dressing versus polyurethane dressing – proportion of ulcers completely healed (all stages)



Figure 677: Gauze dressing versus polyurethane dressing – proportion of ulcers completely healed (stage II)



Figure 678: Gauze dressing versus polyurethane dressing – proportion of ulcers worsened



Figure 679: Gauze dressing versus polyurethane dressing – proportion of ulcers decreased in ulcer stage (stage II)



Figure 680: Gauze dressing versus polyurethane dressing – proportion of ulcers increased in ulcer stage (stage II)



Figure 681: Gauze dressing versus polyurethane dressing – proportion of patients with maceration



Figure 682: Gauze dressing versus hydrogel – proportion of patients completely healed



Figure 683: Gauze dressing versus hydrogel – proportion of patients worsened



Figure 684: Gauze dressing versus hydrogel – mean percentage reduction in ulcer area



Figure 685: Gauze dressing versus hydrogel – mean healing rate (cm²/day)



Figure 686: Gauze dressing versus hydrogel – mean time to healing (weeks)



Figure 687: Gauze dressing versus hydrogel – mortality

Figure 688: Gauze dressing versus dextranomer – proportion of ulcers improved



Figure 689: Gauze dressing versus dextranomer – proportion of people with adverse events



Figure 690: Gauze dressing versus phenytoin cream – proportion of patients completely healed



Figure 691: Gauze dressing versus phenytoin cream – proportion of ulcers completely healed (all stages – all sites)



Figure 692: Gauze dressing versus phenytoin cream – proportion of ulcers improved



Figure 693: Gauze dressing versus phenytoin cream – proportion of ulcers worsened



Figure 694: Gauze dressing versus phenytoin cream – mortality (all-cause)



Figure 695: Foam dressing versus skin replacement – proportion of patients completely healed



Figure 696: Foam dressing versus skin replacement – proportion of patients with an infection



Figure 697: Foam dressing versus skin replacement – proportion of people with adverse events



Figure 698: Foam dressing versus antibiotic ointment – proportion of patients completely healed



Figure 699: Foam dressing: Allevyn® versus Biatain® – proportion of patients completely healed



Figure 700: Foam dressing: Allevyn® versus Biatain® – mean comfort score at dressing removal



Figure 701: Foam dressing: Allevyn® versus Biatain® – proportion of patients with dressing related adverse events



Figure 702: Foam dressing: Allevyn® versus Biatain® – mortality

Study or Subgroup	Allevyn Events	Allevyn Total	Biatian Events	Biatian Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Amoine 2005	0	14	1	18	100.0%	0.17 [0.00, 8.79]
Total (95% CI)		**14**		**18**	**100.0%**	**0.17 [0.00, 8.79]**
Total events	0		1			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.88 (P = 0.38)



Figure 703: Foam dressing: Mepilex® versus Tielle® – proportion of patients completely healed

Study or Subgroup	Mepilex Events	Mepilex Total	Tielle Events	Tielle Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Meaume 2003	8	18	10	20	100.0%	0.89 [0.45, 1.75]
Total (95% CI)		**18**		**20**	**100.0%**	**0.89 [0.45, 1.75]**
Total events	8		10			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.34 (P = 0.73)



Figure 704: Foam dressing: Mepilex® versus Tielle® – proportion of patients improved

Study or Subgroup	Mepilex Events	Mepilex Total	Tielle Events	Tielle Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Meaume 2003	15	18	19	20	100.0%	0.88 [0.70, 1.10]
Total (95% CI)		**18**		**20**	**100.0%**	**0.88 [0.70, 1.10]**
Total events	15		19			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.12 (P = 0.26)



Figure 705: Foam dressing: Mepilex® versus Tielle® – proportion of patients worsened

Study or Subgroup	Mepilex Events	Mepilex Total	Tielle Events	Tielle Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Meaume 2003	2	18	1	20	100.0%	2.22 [0.22, 22.49]
Total (95% CI)		**18**		**20**	**100.0%**	**2.22 [0.22, 22.49]**
Total events	2		1			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.68 (P = 0.50)



Figure 706: Foam dressing: Mepilex® versus Tielle® – proportion of patients with maceration

Study or Subgroup	Mepilex Events	Mepilex Total	Tielle Events	Tielle Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Meaume 2003	0	18	3	20	100.0%	0.13 [0.01, 1.38]
Total (95% CI)		**18**		**20**	**100.0%**	**0.13 [0.01, 1.38]**
Total events	0		3			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.69 (P = 0.09)



Figure 707: Foam dressing: Mepilex® versus Tielle® – proportion of patients reporting odour

Study or Subgroup	Mepilex Events	Mepilex Total	Tielle Events	Tielle Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Meaume 2003	0	18	3	20	100.0%	0.13 [0.01, 1.38]
Total (95% CI)		**18**		**20**	**100.0%**	**0.13 [0.01, 1.38]**
Total events	0		3			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.69 (P = 0.09)



Figure 708: Foam dressing: Mepilex® versus Tielle® – proportion of patients with adverse events

Study or Subgroup	Mepilex Events	Mepilex Total	Tielle Events	Tielle Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Meaume 2003	1	18	3	20	100.0%	0.37 [0.04, 3.25]
Total (95% CI)		**18**		**20**	**100.0%**	**0.37 [0.04, 3.25]**
Total events	1		3			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.90 (P = 0.37)



Figure 709: Foam dressing: Mepilex® versus Tielle® – mortality

Study or Subgroup	Mepilex Events	Mepilex Total	Tielle Events	Tielle Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Meaume 2003	1	18	1	20	100.0%	1.11 [0.07, 16.49]
Total (95% CI)		**18**		**20**	**100.0%**	**1.11 [0.07, 16.49]**
Total events	1		1			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.08 (P = 0.94)



<Insert Note here>

Figure 710: Hydrogel dressing versus foam dressing – proportion of ulcers completely healed (all stages)

Study or Subgroup	Hydrogel Events	Hydrogel Total	Foam Events	Foam Total	Weight	Risk Ratio M-H, Fixed, 95% CI
21.1.2 Foam						
Sopata 2002	15	20	15	18	100.0%	0.90 [0.65, 1.25]
Subtotal (95% CI)		**20**		**18**	**100.0%**	**0.90 [0.65, 1.25]**
Total events	15		15			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.63 (P = 0.53)

Test for subgroup differences: Not applicable



Figure 711: Hydrogel dressing versus foam dressing – proportion of ulcers improved (all stages)



Figure 712: Hydrogel dressing versus foam dressing – mean rate of healing of healed ulcers (cm²/day) (grade II)



Figure 713: Hydrogel dressing versus foam dressing – mean rate of healing of healed ulcers (cm²/day) (grade III)



Figure 714: Hydrogel dressing versus foam dressing – mean rate of healing of improved ulcers (cm²/day) (grade III)



Figure 715: Hydrogel dressing versus foam dressing – mortality



Figure 716: Hydrogel dressing versus dextranomer – proportion of patients reporting pain at dressing application



Figure 717: Hydrogel dressing versus dextranomer –mortality



Figure 718: Hydrogel, foam dressing or transparent film versus different types of dressing – proportion of patients completely healed



Figure 719: Hydrogel, foam dressing or transparent film dressing versus different types of dressing – proportion of patients reporting the application of the dressing as comfortable



Figure 720: Hydrogel, foam dressing or transparent film dressing versus different types of dressing – proportion of patients reporting discomfort at dressing removal



Figure 721: Hydrogel, foam dressing or transparent film dressing versus different types of dressing – proportion of people with adverse events



Figure 722: Hydrogel, foam dressing or transparent film dressing versus different types of dressing – mortality



Figure 723: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with intermittent ulcer pain



Figure 724: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with continuous ulcer pain



Figure 725: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with slight pain at dressing removal



Figure 726: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with severe pain at dressing removal



Figure 727: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with discomfort



Figure 728: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with maceration



Figure 729: Hydrogel dressing: Sterigel® versus Intrasite® – mortality (all-cause)

Figure 730: Protease modulating matrix versus impregnated gauze dressing – proportion of patients completely healed



Figure 731: Protease modulating matrix versus impregnated gauze dressing – proportion of patients with adverse events



Figure 732: Protease modulating matrix versus impregnated gauze dressing – mortality (all-cause)



Figure 733: Figure 135. Polyurethane dressing versus different types of dressing – mean time to healing (days) (all stages)



Figure 734: Polyurethane dressing versus different types of dressing – mean time to healing (days) (stage II)



Figure 735: Polyurethane dressing versus different types of dressing – mean time to healing (days) (stage III)



Figure 736: Polyurethane dressing versus different types of dressing – mean difference in PUSH score



Figure 737: Polyurethane dressing versus different types of dressing – proportion of patients with systemic worsening



Figure 738: Polyurethane dressing versus different types of dressing – proportion of patients with localized adverse events



Figure 739: Polyurethane dressing versus different types of dressing – mortality (all-cause)



Figure 740: Alginate dressing versus silver alginate dressing – proportion of patients worsened



Figure 741: Alginate dressing versus silver alginate dressing – mean percentage reduction in ulcer area



Figure 742: Alginate dressing versus silver alginate dressing – absolute cm² decrease in ulcer area



Figure 743: Alginate dressing versus silver alginate dressing – mean rate of healing (cm²/day)



Figure 744: Alginate dressing versus silver alginate dressing – proportion of patients with an infection



Figure 745: Alginate dressing versus silver alginate dressing – mean mASEPSIS index at and of treatment



Figure 746: Alginate dressing versus silver alginate dressing – proportion of patients with poor acceptability and/or tolerability



Figure 747: Alginate dressing versus silver alginate dressing –mortality (all-cause)



Figure 748: Alginate dressing versus dextranomer – proportion of patients with > 75% reduction in ulcer area



Figure 749: Alginate dressing versus dextranomer – proportion of patients with > 40% reduction in ulcer area



Figure 750: Alginate dressing versus dextranomer – proportion of patients worsened or stagnated